Effect of peripherally administered leptin antagonist on whole body metabolism and bone microarchitecture and biomechanical properties in the mouse

American Journal of Physiology - Endocrinology and Metabolism

Volumn 306, Issue 1, 2014, Pages

  Solomon, Gili ^a   Atkins, Ayelet ^a   Shahar, Ron ^a   Gertler, Arieh ^a   Monsonego Ornan, Efrat ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Insulin resistance; Leptin signaling; Microcomputed tomography; Obesity

Indexed keywords

ALIZARIN; CALCEIN; CHOLESTEROL; GLUCOSE; INSULIN; PEPTIDE HORMONE ANTAGONIST; SUPERACTIVE MOUSE LEPTIN ANTAGONIST; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE METABOLISM; BONE STRUCTURE; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG HALF LIFE; FOOD INTAKE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; INSULIN RESISTANCE; LUMBAR VERTEBRA; MORPHOMETRICS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TIBIA; TRABECULAR BONE; WEIGHT GAIN;

EID: 84891507109     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00155.2013     Document Type: Article

References (91)

1. Ables GP, Perrone CE, Orentreich D, Orentreich N. Methioninerestricted C57BL/6J mice are resistant to diet-induced obesity and insulin resistance but have low bone density. PLoS One 7: e51357, 2012.
2. Albala C, Yanez M, Devoto E, Sostin C, Zeballos L, Santos JL. Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord 20: 1027-1032, 1996.
3. Ambati S, Li Q, Rayalam S, Hartzell DL, Della-Fera MA, Hamrick MW, Baile CA. Central leptin versus ghrelin: effects on bone marrow adiposity and gene expression. Endocrine 37: 115-123, 2010.
4. Amling M, Takeda S, Karsenty G. A neuro (endo)crine regulation of bone remodeling. Bioessays 22: 970-975, 2000.
5. Aǧbaht K, Gürlek A, Karakaya J, Bayraktar M. Circulating adiponectin represents a biomarker of the association between adiposity and bone mineral density. Endocrine 35: 371-379, 2009.
6. Barros CC, Haro A, Russo FJ, Schadock I, Almeida SS, Reis FC, Moraes MR, Haidar A, Hirata AE, Mori M, Bacurau RF, Würtele M, Bader M, Pesquero JB, Araujo RC. Bradykinin inhibits hepatic gluconeogenesis in obese mice. Lab Invest 92: 1419-1427, 2012.
7. Bartell SM, Rayalam S, Ambati S, Gaddam DR, Hartzell DL, Hamrick M, She JX, Della-Fera MA, Baile CA. Central (ICV) leptin injection increases bone formation, bone mineral density, muscle mass, serum IGF-1, and the expression of osteogenic genes in leptin-deficient ob/ob mice. J Bone Miner Res 26: 1710-1720, 2011.
8. Bartelt A, Beil FT, Schinke T, Roeser K, Ruether W, Heeren J, Niemeier A. Apolipoprotein E-dependent inverse regulation of vertebral bone and adipose tissue mass in C57Bl/6 mice: modulation by dietinduced obesity. Bone 47: 736-745, 2010.
9. Barthel A, Schmoll D. Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 285: E685-E692, 2003.
10. Cakir I, Perello M, Lansari O, Messier NJ, Vaslet CA, Nillni EA. Hypothalamic Sirt1 regulates food intake in a rodent model system. PLoS One 4: e8322, 2009.
11. Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res 6: 30, 2011.
12. Cao JJ, Gregoire BR, Gao H. High-fat diet decreases cancellous bone mass but has no effect on cortical bone mass in the tibia in mice. Bone 44: 1097-1104, 2009.
13. Cao JJ, Sun L, Gao H. Diet-induced obesity alters bone remodeling leading to decreased femoral trabecular bone mass in mice. Ann NY Acad Sci 1192: 292-297, 2010.
14. Carson EA, Kenney-Hunt JP, Pavlicev M, Bouckaert KA, Chinn AJ, Silva MJ, Cheverud JM. Weak genetic relationship between trabecular bone morphology and obesity in mice. Bone 51: 46-53, 2012.
15. Challa TD, Rais Y, Ornan EM. Effect of adiponectin on ATDC5 proliferation, differentiation and signaling pathways. Mol Cell Endocrinol 323: 282-291, 2010.
16. Chapnik N, Solomon G, Genzer Y, Miskin R, Gertler A, Froy O. A superactive leptin antagonist alters metabolism and locomotion in highleptin mice. J Endocrinol 217: 283-290, 2013.
17. Choi Y, Kim Y, Park S, Lee KW, Park T. Indole-3-carbinol prevents diet-induced obesity through modulation of multiple genes related to adipogenesis, thermogenesis or inflammation in the visceral adipose tissue of mice. J Nutr Biochem 23: 1732-1739, 2012.
18. Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 14: 543-553, 2007.
19. Delporte ML, El Mkadem SA, Quisquater M, Brichard SM. Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice. Am J Physiol Endocrinol Metab 287: E446-E453, 2004.
20. Diaz-Delfin J, Hondares E, Iglesias R, Giralt M, Caelles C, Villarroya F. TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. Endocrinology 153: 4238-4245, 2012.
21. Dietrich MO, Antunes C, Geliang G, Liu ZW, Borok E, Nie Y, Xu AW, Souza DO, Gao Q, Diano S, Gao XB, Horvath TL. Agrp neurons mediate Sirt1's action on the melanocortin system and energy balance: roles for Sirt1 in neuronal firing and synaptic plasticity. J Neurosci 30: 11815-11825, 2010.
22. Douen AG, Ramlal T, Rastogi S, Bilan PJ, Cartee GD, Vranic M, Holloszy JO, Klip A. Exercise induces recruitment of the "insulinresponsive glucose transporter". Evidence for distinct intracellular insulinand exercise-recruitable transporter pools in skeletal muscle. J Biol Chem 265: 13427-13430, 1990.
23. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000.
24. Elefteriou F, Takeda S, Ebihara K, Magre J, Patano N, Kim CA, Ogawa Y, Liu X, Ware SM, Craigen WJ, Robert JJ, Vinson C, Nakao K, Capeau J, Karsenty G. Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci USA 101: 3258-3263, 2004.
25. Elinav E, Ali M, Bruck R, Brazowski E, Phillips A, Shapira Y, Katz M, Solomon G, Halpern Z, Gertler A. Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function. Hepatology 49: 278-286, 2009.
26. Elinav E, Niv-Spector L, Katz M, Price TO, Ali M, Yacobovitz M, Solomon G, Reicher S, Lynch JL, Halpern Z, Banks WA, Gertler A. Pegylated leptin antagonist is a potent orexigenic agent: preparation and mechanism of activity. Endocrinology 150: 3083-3091, 2009.
27. Evans BA, Bull MJ, Kench RC, Fox RE, Morgan LD, Stevenson AE, Gevers EF, Perry MJ, Wells T. The influence of leptin on trabecular architecture and marrow adiposity in GH-deficient rats. J Endocrinol 208: 69-79, 2011.
28. Fan S, Zhang Y, Hu N, Sun Q, Ding X, Li G, Zheng B, Gu M, Huang F, Sun YQ, Zhou Z, Lu X, Huang C, Ji G. Extract of Kuding tea prevents high-fat diet-induced metabolic disorders in C57BL/6 mice via liver X receptor (LXR) beta antagonism. PLoS One 7: e51007, 2012.
29. Ferber S, Meyerovitch J, Kriauciunas KM, Kahn CR. Vanadate normalizes hyperglycemia and phosphoenolpyruvate carboxykinase mRNA levels in ob/ob mice. Metabolism 43: 1346-1354, 1994.
30. Ferré P, Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 12, Suppl 2: 83-92, 2010.
31. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 395: 763-770, 1998.
32. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 393: 7-20, 2006.
33. Fujita Y, Watanabe K, Maki K. Serum leptin levels negatively correlate with trabecular bone mineral density in high-fat diet-induced obesity mice. J Musculoskelet Neuronal Interact 12: 84-94, 2012.
34. Hamrick MW, Della-Fera MA, Choi YH, Pennington C, Hartzell D, Baile CA. Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice. J Bone Miner Res 20: 994-1001, 2005.
35. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 34: 376-383, 2004.
36. Heep H, Wedemeyer C, Wegner A, Hofmeister S, von Knoch M. Differences in trabecular bone of leptin-deficient ob/ob mice in response to biomechanical loading. Int J Biol Sci 4: 169-175, 2008.
37. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, Mawatari H, Shibata W, Kitani H, Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab 16: 44-54, 2012.
38. Ionova-Martin SS, Do SH, Barth HD, Szadkowska M, Porter AE, Ager JW 3rd, Ager JW Jr, Alliston T, Vaisse C, Ritchie RO. Reduced size-independent mechanical properties of cortical bone in high-fat dietinduced obesity. Bone 46: 217-225, 2010.
39. Ionova-Martin SS, Wade JM, Tang S, Shahnazari M, Ager JW 3rd, Lane NE, Yao W, Alliston T, Vaisse C, Ritchie RO. Changes in cortical bone response to high-fat diet from adolescence to adulthood in mice. Osteoporos Int 22: 2283-2293, 2011.
40. Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson RA, Kahn BB, Magnuson MA. Deletion of PPARgamma in adipose tissues of mice protects against high fat dietinduced obesity and insulin resistance. Proc Natl Acad Sci USA 102: 6207-6212, 2005.
41. Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 316: 17-24, 2006.
42. Kang JS, Lee WK, Yoon WK, Kim N, Park SK, Park HK, Ly SY, Han SB, Yun J, Lee CW, Lee K, Lee KH, Park SK, Kim HM. A combination of grape extract, green tea extract and L-carnitine improves high-fat diet-induced obesity, hyperlipidemia and non-alcoholic fatty liver disease in mice. Phytother Res 25: 1789-1795, 2011.
43. Kang SI, Shin HS, Kim HM, Hong YS, Yoon SA, Kang SW, Kim JH, Ko HC, Kim SJ. Anti-obesity properties of a Sasa quelpaertensis extract in high-fat diet-induced obese mice. Biosci Biotechnol Biochem 76: 755-761, 2012.
44. Karnieli E, Armoni M. Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology. Am J Physiol Endocrinol Metab 295: E38-E45, 2008.
45. Karsenty G. Leptin controls bone formation through a hypothalamic relay. Recent Prog Horm Res 56: 401-415, 2001.
46. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time Quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408, 2001.
47. Kitchens RL. Role of CD14 in cellular recognition of bacterial lipopolysaccharides. Chem Immunol 74: 61-82, 2000.
48. Kobayashi T, Kronenberg H. Minireview: transcriptional regulation in development of bone. Endocrinology 146: 1012-1017, 2005.
49. Kronenberg HM. Developmental regulation of the growth plate. Nature 423: 332-336, 2003.
50. Kume K, Satomura K, Nishisho S, Kitaoka E, Yamanouchi K, Tobiume S, Nagayama M. Potential role of leptin in endochondral ossification. J Histochem Cytochem 50: 159-169, 2002.
51. Lee MS, Kim CT, Kim Y. Green tea (-)-epigallocatechin-3-gallate reduces body weight with regulation of multiple genes expression in adipose tissue of diet-induced obese mice. Ann Nutr Metab 54: 151-157, 2009.
52. Lee YS, Cha BY, Choi SS, Choi BK, Yonezawa T, Teruya T, Nagai K, Woo JT. Nobiletin improves obesity and insulin resistance in high-fat diet-induced obese mice. J Nutr Biochem 24: 156-162, 2013.
53. Li H, Xu M, Lee J, He C, Xie Z. Leucine supplementation increases SIRT1 expression and prevents mitochondrial dysfunction and metabolic disorders in high-fat diet-induced obese mice. Am J Physiol Endocrinol Metab 303: E1234-E1244, 2012.
54. Lin S, Thomas TC, Storlien LH, Huang XF. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int J Obes Relat Metab Disord 24: 639-646, 2000.
55. Luquet S, Perez FA, Hnasko TS, Palmiter RD. NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates. Science 310: 683-685, 2005.
56. Ma H, Torvinen S, Silvennoinen M, Rinnankoski-Tuikka R, Kainulainen H, Morko J, Peng Z, Kujala UM, Rahkila P, Suominen H. Effects of diet-induced obesity and voluntary wheel running on bone properties in young male C57BL/6J mice. Calcif Tissue Int 86: 411-419, 2010.
57. Maeda H, Hosokawa M, Sashima T, Murakami-Funayama K, Miyashita K. Anti-obesity and anti-diabetic effects of fucoxanthin on dietinduced obesity conditions in a murine model. Mol Med Rep 2: 897-902, 2009.
58. Maor G, Rochwerger M, Segev Y, Phillip M. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers. J Bone Miner Res 17: 1034-1043, 2002.
59. Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 20: 516-522, 2000.
60. Myers MG, Cowley MA, Munzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol 70: 537-556, 2008.
61. Ohlsson C, Vidal O. Effects of growth hormone and insulin-like growth factors on human osteoblasts. Eur J Clin Invest 28: 184-186, 1998.
62. Patsch JM, Kiefer FW, Varga P, Pail P, Rauner M, Stupphann D, Resch H, Moser D, Zysset PK, Stulnig TM, Pietschmann P. Increased bone resorption and impaired bone microarchitecture in short-term and extended high-fat diet-induced obesity. Metabolism 60: 243-249, 2011.
63. Pautke C, Vogt S, Tischer T, Wexel G, Deppe H, Milz S, Schieker M, Kolk A. Polychrome labeling of bone with seven different fluorochromes: enhancing fluorochrome discrimination by spectral image analysis. Bone 37: 441-445, 2005.
64. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 93: 693-704, 1998.
65. Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW, Guarente L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPARgamma. Nature 429: 771-776, 2004.
66. Pogoda P, Egermann M, Schnell JC, Priemel M, Schilling AF, Alini M, Schinke T, Rueger JM, Schneider E, Clarke I, Amling M. Leptin inhibits bone formation not only in rodents, but also in sheep. J Bone Miner Res 21: 1591-1599, 2006.
67. Premaratna SD, Manickam E, Begg DP, Rayment DJ, Hafandi A, Jois M, Cameron-Smith D, Weisinger RS. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice. Int J Obes (Lond) 36: 233-243, 2012.
68. Reid IR. Fat and bone. Arch Biochem Biophys 503: 20-27, 2010.
69. Reid IR. Relationships among body mass, its components, and bone. Bone 31: 547-555, 2002.
70. Reid IR, Evans MC, Ames RW. Volumetric bone density of the lumbar spine is related to fat mass but not lean mass in normal postmenopausal women. Osteoporos Int 4: 362-367, 1994.
71. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol Endocrinol Metab 265: E655-E659, 1993.
72. Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyteenriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab 303: E334-E351, 2012.
73. Reul BA, Becker DJ, Ongemba LN, Bailey CJ, Henquin JC, Brichard SM. Improvement of glucose homeostasis and hepatic insulin resistance in ob/ob mice given oral molybdate. J Endocrinol 155: 55-64, 1997.
74. Revilla M, Villa LF, Sanchez-Atrio A, Hernandez ER, Rico H. Influence of body mass index on the age-related slope of total and regional bone mineral content. Calcif Tissue Int 61: 134-138, 1997.
75. Ribot C, Tremollieres F, Pouilles JM. The effect of obesity on postmenopausal bone loss and the risk of osteoporosis. Adv Nutr Res 9: 257-271, 1994.
76. Roche HM, Noone E, Sewter C, Mc Bennett S, Savage D, Gibney MJ, O'Rahilly S, Vidal-Puig AJ. Isomer-dependent metabolic effects of conjugated linoleic acid: insights from molecular markers sterol regulatory element-binding protein-1c and LXRalpha. Diabetes 51: 2037-2044, 2002.
77. Romics L Jr, Mandrekar P, Kodys K, Velayudham A, Drechsler Y, Dolganiuc A, Szabo G. Increased lipopolysaccharide sensitivity in alcoholic fatty livers is independent of leptin deficiency and toll-like receptor 4 (TLR4) or TLR2 mRNA expression. Alcohol Clin Exp Res 29: 1018-1026, 2005.
78. Salomon G, Niv-Spector L, Gussakovsky EE, Gertler A. Large-scale preparation of biologically active mouse and rat leptins and their L39A/ D40A/F41A muteins which act as potent antagonists. Protein Expr Purif 47: 128-136, 2006.
79. Shen L, Tso P, Woods SC, Clegg DJ, Barber KL, Carey K, Liu M. Brain apolipoprotein E: an important regulator of food intake in rats. Diabetes 57: 2092-2098, 2008.
80. Shpilman M, Niv-Spector L, Katz M, Varol C, Solomon G, Ayalon-Soffer M, Boder E, Halpern Z, Elinav E, Gertler A. Development and characterization of high affinity leptins and leptin antagonists. J Biol Chem 286: 4429-4442, 2011.
81. Simsa-Maziel S, Monsonego-Ornan E. Interleukin-1 promotes proliferation and inhibits differentiation of chondrocytes through a mechanism involving down-regulation of FGFR-3 and p21. Endocrinology 153: 2296-2310, 2012.
82. Simsa-Maziel S, Zaretsky J, Reich A, Koren Y, Shahar R, Monsonego-Ornan E. IL-1RI participates in normal growth plate development and bone modeling. Am J Physiol Endocrinol Metab 305: E15-E21, 2013.
83. Steppan CM, Crawford DT, Chidsey-Frink KL, Ke H, Swick AG. Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept 92: 73-78, 2000.
84. Stevenson AE, Evans BA, Gevers EF, Elford C, McLeod RW, Perry MJ, El-Kasti MM, Coschigano KT, Kopchick JJ, Evans SL, Wells T. Does adiposity status influence femoral cortical strength in rodent models of growth hormone deficiency? Am J Physiol Endocrinol Metab 296: E147-E156, 2009.
85. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317, 2002.
86. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol 4: 295-300, 2004.
87. Turner CH, Burr DB. Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608, 1993.
88. Vessal M, Mishra S, Moulik S, Murphy LJ. Prohibitin attenuates insulin-stimulated glucose and fatty acid oxidation in adipose tissue by inhibition of pyruvate carboxylase. FEBS J 273: 568-576, 2006.
89. Weizmann S, Tong A, Reich A, Genina O, Yayon A, Monsonego-Ornan E. FGF upregulates osteopontin in epiphyseal growth plate chondrocytes: implications for endochondral ossification. Matrix Biol 24: 520-529, 2005.
90. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, Amemiya-Kudo M, Tomita S, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Nagai R, Ishibashi S, Yamada N. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277: 19353-19357, 2002.
91. Zhang W, Ambati S, Della-Fera MA, Choi YH, Baile CA, Andacht TM. Leptin modulated changes in adipose tissue protein expression in ob/ob mice. Obesity (Silver Spring) 19: 255-261, 2011.